Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Glufosfamide

5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.

Trial Locations (7)

10011

St. Vincent's Comprehensive Cancer Center, New York

33612

H. Lee Moffitt Cancer Center, Tampa

63110

Washington University School of Medicine, Division of Oncology, St Louis

85260

Premiere Oncology of Arizona, Scottsdale

85724

Arizona Cancer Center, Tucson

87131

University of New Mexico Cancer Research and Treatment Center, Albuquerque

94305

Stanford Cancer Center, Stanford

Sponsors
All Listed Sponsors
collaborator

Threshold Pharmaceuticals

INDUSTRY

lead

Eleison Pharmaceuticals LLC.

INDUSTRY